What is Formation Bio?
Formation Bio operates at the intersection of biotechnology and software engineering, utilizing a sophisticated technology platform to modernize the clinical development lifecycle. Unlike traditional pharmaceutical entities, the company focuses on acquiring clinical-stage assets and applying its proprietary tech stack to enhance trial efficiency, accelerate completion timelines, and ensure superior data integrity. This approach allows the firm to unlock substantial value from existing drug programs while simultaneously reducing the time-to-market for life-saving treatments. By integrating high-fidelity data analytics into the core of its operations, Formation Bio is redefining the standard for how clinical-stage drugs are brought to market, effectively bridging the gap between scientific innovation and patient care.
How much funding has Formation Bio raised?
Formation Bio has raised a total of $372M across 1 funding round:
Series D
$372M
Series D (2024): $372M with participation from Sequoia Capital, Emerson Collective, Andreessen Horowitz, and Sanofi
Key Investors in Formation Bio
Sequoia Capital
A premier global venture capital firm with an unparalleled track record of partnering with entrepreneurs to build market-leading companies across various stages of growth.
Emerson Collective
An investment and philanthropic organization that supports innovators and entrepreneurs dedicated to addressing complex societal challenges through rigorous thinking and audacious ideas.
Andreessen Horowitz
A prominent American venture capital firm that provides strategic backing to both early-stage startups and established growth-stage companies across the technology landscape.
What's next for Formation Bio?
With the successful closure of this major strategic investment, Formation Bio is well-positioned to scale its operations and expand its portfolio of clinical-stage assets. The company's roadmap likely involves deepening its integration with global pharmaceutical partners to further refine its trial design capabilities. As the firm continues to demonstrate the efficacy of its platform, it is expected to attract further interest from institutional investors looking to capitalize on the digital transformation of the life sciences sector. The focus remains on achieving faster trial completion rates and maintaining high-quality data standards, which will be instrumental in securing future partnerships and potentially expanding into new therapeutic areas where traditional development models have historically struggled to deliver results.
See full Formation Bio company page
